What the Research Shows on Reglan and Tardive Dyskinesia

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

From General Health Awareness to Occupational Risk

If you or a loved one has taken Reglan (metoclopramide) and developed uncontrollable muscle movements, you may be concerned about tardive dyskinesia. Medical research has long explored the connection between this medication and movement disorders, building on decades of clinical observation and adverse event reporting. This page summarizes key study findings and adverse event reports to help you understand the evidence.

Reglan and Tardive Dyskinesia: A Critical Link

Reglan (metoclopramide) is a medication approved for short-term use in adults with symptomatic gastroesophageal reflux and diabetic gastroparesis. However, its association with tardive dyskinesia (TD), a potentially irreversible movement disorder, has led to significant litigation, particularly in Florida. Understanding the statute of limitations for filing a Reglan TD claim in Florida requires careful consideration of the drug's labeling, the timeline of exposure and harm, and the adequacy of warnings provided to patients. The FDA-approved labeling for Reglan includes a boxed warning stating that metoclopramide can cause tardive dyskinesia, a serious and potentially irreversible movement disorder (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The risk of developing TD increases with the duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD, and healthcare providers are instructed to use the drug for the shortest duration necessary, with periodic reassessment of the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with symptomatic gastroesophageal reflux, the maximum duration of Reglan treatment is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In patients with diabetic gastroparesis, treatment should not exceed 12 weeks, and if longer use is unavoidable, routine monitoring for TD signs and symptoms is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Despite these warnings, many patients were prescribed Reglan for extended periods, often exceeding the recommended 12-week limit. This prolonged exposure increases the risk of developing TD, which may manifest as involuntary movements of the face, tongue, trunk, or extremities (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The labeling also notes that metoclopramide may suppress or partially suppress the signs of TD, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This masking effect can complicate the timeline between exposure and documented harm, as patients may not recognize symptoms until after discontinuing the drug.

Florida's Statute of Limitations for Reglan TD Claims

In Florida, the statute of limitations for personal injury claims, including those related to prescription drug injuries like TD, is generally four years from the date the injury was discovered or should have been discovered. However, this timeline can be influenced by factors such as the adequacy of warnings. If a patient was not adequately informed of the risk of TD, the discovery rule may apply, meaning the statute of limitations begins when the patient knew or reasonably should have known that Reglan caused their TD. Given that Reglan's labeling includes a boxed warning about TD, patients who received the medication after the warning was added may have a shorter window to file a claim, as they are presumed to have been informed of the risk. Settlement-related considerations for affected patients in Florida often hinge on the duration of Reglan use and the severity of TD symptoms. Patients who used Reglan for longer than 12 weeks, especially those who developed TD after prolonged exposure, may have stronger claims. The labeling explicitly states that the risk of TD increases with treatment duration and cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Additionally, Reglan is not recommended for pediatric use due to the risk of TD and other extrapyramidal symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397), which may be relevant in cases involving younger patients. The timeline between exposure and documented harm is critical for statute of limitations calculations. TD can develop months or even years after starting Reglan, and symptoms may persist or worsen after discontinuation. The labeling advises immediate discontinuation of Reglan if signs or symptoms of TD occur (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, because TD can be irreversible, patients may not realize the connection to Reglan until later, especially if they were not warned about the risk. This delay can affect the statute of limitations, as the clock may start ticking only when the patient discovers the link.

Key Evidence and Legal Considerations

In summary, Florida patients considering a Reglan TD settlement must be aware of the four-year statute of limitations, which may be extended under the discovery rule if warnings were inadequate. The FDA labeling provides clear evidence that Reglan carries a risk of TD, particularly with long-term use, and that the drug is only approved for short-term treatment. Patients who used Reglan beyond 12 weeks or developed TD after prolonged exposure should consult legal counsel to assess their claim's viability. The key evidence includes the boxed warning, the 12-week treatment limit, and the contraindication for patients with a history of TD, all of which underscore the importance of timely action.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Reglan tardive dyskinesia claims in Florida?

In Florida, the statute of limitations for personal injury claims, including those related to Reglan-induced tardive dyskinesia, is generally four years from the date the injury was discovered or should have been discovered. However, the discovery rule may extend this timeline if the patient was not adequately warned about the risk of TD.

How does the FDA labeling affect Reglan TD claims?

The FDA-approved labeling for Reglan includes a boxed warning about the risk of tardive dyskinesia, especially with long-term use. This warning can impact the statute of limitations because patients who received Reglan after the warning was added are presumed to have been informed of the risk, potentially shortening the window to file a claim.

What evidence is important for a Reglan TD settlement in Florida?

Key evidence includes the duration of Reglan use (especially beyond 12 weeks), the presence of a tardive dyskinesia diagnosis, and documentation that the patient was not adequately warned about the risk. The FDA labeling and medical records are critical.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Reglan Labeling

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.